高危前列腺癌适度简短雄激素抑制联合立体定向放疗的长期结局:FASTR/FASTR-2试验更新
FASTR与FASTR-2两项单中心试验评估高危前列腺癌患者接受超低分次立体定向消融放疗(SABR)联合雄激素剥夺治疗(ADT)的长期结局。44例可分析患者中,FASTR组5年晚期≥3级泌尿生殖/胃肠道毒性累积发生率为32%,FASTR-2组为11%;5年生化无失败生存率、无远处转移生存率、前列腺癌特异性生存率和总生存率分别为72%、90%、92%和83%。作者认为通过优化技术实施和严格遵守危及器官剂量约束,SABR可安全用于高危前列腺癌,但需更大规模随机试验进一步了解该方法的疗效与耐受性。
要点
- FASTR组5年晚期≥3级泌尿生殖/胃肠道毒性累积发生率为32%,FASTR-2组为11%。
- 5年生化无失败生存率72%、无远处转移生存率90%、前列腺癌特异性生存率92%、总生存率83%。
- 作者认为通过优化技术实施和严格遵守危及器官剂量约束,SABR可安全用于高危前列腺癌。
核心结论
- 作者认为通过优化技术实施、尤其严格遵守危及器官剂量约束,SABR可安全用于高危前列腺癌。
- FASTR与FASTR-2的临床结局与更标准的分次方案联合ADT大体相当,但进一步修改可能改善疾病控制。
- 作者指出需要更大规模随机试验以更好地了解该方法的疗效与耐受性。
研究设计与样本
- FASTR与FASTR-2为单中心试验,纳入局限期高危前列腺癌患者,条件为年龄≥70岁、脆弱老年人量表评分≥3分或拒绝标准治疗。
- FASTR于2011年至2015年入组19例,接受前列腺40 Gy和盆腔淋巴结25 Gy,5次每周分割,联合12个月ADT。
- FASTR-2于2015年至2017年入组同一机构30例,仅接受前列腺35 Gy,5次每周分割,联合18个月ADT。
- 回顾性评估更新后的毒性和结局,采用Kaplan-Meier法计算生化无失败生存率、无远处转移生存率、前列腺癌特异性生存率和总生存率。
- 44例符合分析条件,FASTR组16例,FASTR-2组28例;34例(77%)年龄>70岁。
主要发现
- 高危特征包括Gleason评分≥8分(20例,46%)、T3-T4期疾病(12例,27%)和基线前列腺特异性抗原>20(22例,50%)。
- 中位随访6.4年。
- 5年晚期≥3级泌尿生殖/胃肠道毒性累积发生率FASTR组为32%,FASTR-2组为11%。
- 5年生化无失败生存率、无远处转移生存率、前列腺癌特异性生存率和总生存率分别为72%、90%、92%和83%。
关键数值与推荐
- FASTR方案:前列腺40 Gy和盆腔淋巴结25 Gy,5次每周分割,联合12个月ADT。
- FASTR-2方案:前列腺35 Gy,5次每周分割,联合18个月ADT。
- 5年晚期≥3级泌尿生殖/胃肠道毒性累积发生率FASTR组32% vs FASTR-2组11%。
- 5年生化无失败生存率72%、无远处转移生存率90%、前列腺癌特异性生存率92%、总生存率83%。
临床怎么用
- 作者认为通过优化技术实施、尤其严格遵守危及器官剂量约束,SABR可安全用于高危前列腺癌。
- 作者指出FASTR与FASTR-2的临床结局与更标准的分次方案联合ADT大体相当,但进一步修改可能改善疾病控制。
- 作者指出需要更大规模随机试验以更好地了解该方法的疗效与耐受性。
局限性
- FASTR与FASTR-2为单中心试验。
- FASTR入组19例、FASTR-2入组30例,可分析44例。
- 毒性及结局为回顾性评估。
- 作者指出需要更大规模随机试验以更好地了解该方法的疗效与耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is limited data on the long-term outcomes of ultrahypofractionated radiation therapy in high-risk prostate cancer. The FASTR and FASTR-2 trials were designed to assess the tolerability of stereotactic ablative radiation therapy (SABR) in this context. Herein, the long-term results are reported. METHODS AND MATERIALS: Eligible patients had localized high-risk prostate cancer and were either ≥70 years old, had a score of ≥3 on the Vulnerable Elderly Scale, or declined standard therapy. Nineteen patients from a single institution were enrolled on FASTR between 2011 and 2015. They received 40 Gy to the prostate and 25 Gy to the pelvic lymph nodes in 5 weekly fractions, with 12 months of androgen deprivation therapy (ADT). Thirty patients from the same institution were enrolled on FASTR-2 between 2015 and 2017. They received 35 Gy to the prostate alone in 5 weekly fractions, with 18 months of ADT. Updated toxicity and outcomes were assessed retrospectively. Kaplan-Meier estimates were calculated for biochemical failure-free survival, freedom from distant metastases, prostate cancer-specific survival, and overall survival. RESULTS: Forty-four patients were eligible for analysis, 16 from FASTR and 28 from FASTR-2. Thirty-four patients (77%) were >70 years old. High-risk features included Gleason score ≥8 (n = 20, 46%), T3-T4 disease (n = 12, 27%), and baseline prostate-specific antigen > 20 (n = 22, 50%). Median follow-up was 6.4 years. The 5-year cumulative incidence of late grade ≥3 genitourinary/gastrointestinal toxicity was 32% in FASTR and 11% in FASTR-2. At 5 years, the combined rates of biochemical failure-free survival, freedom from distant metastases, prostate cancer-specific survival, and overall survival were 72%, 90%, 92%, and 83%, respectively. CONCLUSIONS: SABR can be safely delivered in high-risk prostate cancer by optimizing technical delivery, particularly with adherence to strict dose constraints for organs at risk. The clinical outcomes in FASTR and FASTR-2 were largely comparable to more standard fractionation schemes plus ADT, but further modifications may improve disease control. Larger randomized trials are necessary to better understand the efficacy and tolerability of this approach.
引用
- Tang T, Rodrigues G, Warner A, et al. Long-Term Outcomes Following Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy in High-Risk Prostate Cancer: Update From the FASTR/FASTR-2 Trials. Pract Radiat Oncol. 2023. PMID: 37791942. doi:10.1016/j.prro.2023.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。